丙型肝炎直接抗病毒疗法的药物相互作用

被引：1

作者：

王琴

魏来

机构：

[1] 北京大学人民医院北京大学肝病研究所丙型肝炎和肝病免疫治疗北京市重点实验室

来源：

中华传染病杂志 | 2018年 / 36卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R512.63 [];

学科分类号：

100401 ;

摘要：

<正>

引用

页码：636 / 640

页数：5

共 28 条

[1] EASL Recommendations on Treatment of Hepatitis C 2018 [J].

Pawlotsky J.-M. ;

Negro F. ;

Aghemo A. ;

Berenguer M. ;

Dalgard O. ;

Dusheiko G. ;

Marra F. ;

Puoti M. ;

Wedemeyer H. .

JOURNAL OF HEPATOLOGY, 2018, 69 (02) :461-511

[2] Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia [J].

Ji, F. ;

Wei, B. ;

Yeo, Y. H. ;

Ogawa, E. ;

Zou, B. ;

Stave, C. D. ;

Li, Z. ;

Dang, S. ;

Furusyo, N. ;

Cheung, R. C. ;

Nguyen, M. H. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (05) :550-562

[3]

High prevalence of HIV; HCV; HBV and co-infection and associated risk factors among injecting drug users in Yunnan province; China..[J].Yan-Heng Zhou;Zhi-Hong Yao;Feng-Liang Liu;Hong Li;Li Jiang;Jia-Wu Zhu;Yong-Tang Zheng.PLoS ONE.2017, 8

[4] Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study [J].

Kondili, Loreta A. ;

Gaeta, Giovanni Battista ;

Ieluzzi, Donatella ;

Zignego, Anna Linda ;

Monti, Monica ;

Gori, Andrea ;

Soria, Alessandro ;

Raimondo, Giovanni ;

Filomia, Roberto ;

Di Leo, Alfredo ;

Iannone, Andrea ;

Massari, Marco ;

Corsini, Romina ;

Gulminetti, Roberto ;

Comini, Alberto Gatti ;

Toniutto, Pierluigi ;

Dissegna, Denis ;

Russo, Francesco Paolo ;

Zanetto, Alberto ;

Rumi, Maria Grazia ;

Brancaccio, Giuseppina ;

Danieli, Elena ;

Brunetto, Maurizia Rossana ;

Weimer, Liliana Elena ;

Quaranta, Maria Giovanna ;

Vella, Stefano ;

Puoti, Massimo .

PLOS ONE, 2017, 12 (02)

[5]

Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice..[J].Papatheodoridi Μargarita;Dalekos George N;Goulis John;Manolakopoulos Spilios;Triantos Christos;Zachou Kalliopi;Koukoufiki Argyro;Κourikou Αnastasia;Ζisimopoulos Κonstantinos;Τsoulas Christos;Papatheodoridis George V.Annals of gastroenterology.2017, 5

[6] High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice [J].

Macias, J. ;

Monge, P. ;

Mancebo, M. ;

Merchante, N. ;

Neukam, K. ;

Real, L. M. ;

Pineda, J. A. .

HIV MEDICINE, 2017, 18 (07) :445-451

[7]

THU-282 - Successful management of drug interactions with ritonavir-containing hepatitis C virus regimens in routine clinical practice.[J].F. Marra;A. Boyle;R. Fox;C. Fleming;E. Reilly;M. Heydtmann;S. Datta;M. Priest;S.T. Barclay.Journal of Hepatology.2017, 1

[8]

SAT-238 - Drug-drug interactions of high prevalence in a real world Hepatitis C treatment setting: the impact on treatment and the implications for patient management.[J].M. Coghlan;G. Melanophy;A. O’leary;C. Bergin;S. Norris.Journal of Hepatology.2017, 1

[9] Evaluation of Proton Pump Inhibitor Use on Treatment Outcomes With Ledipasvir and Sofosbuvir in a Real-World Cohort Study [J].